Daxor corporation reports increase in nav to $7.08 per share and 31.8 percent increase in unaudited revenue of operating division for the year ended december 31, 2023

Strong start to 2024 with unaudited revenue climbing 229.1% in first two months of 2024 yoy oak ridge, tn, march 18, 2024 (globe newswire) -- daxor corporation (nasdaq: dxr), the global leader in blood volume measurement technology, announces today the filing of its annual report to shareholders on form n-csr, disclosing its schedule of portfolio holdings as of december 31, 2023. management reported a nav of $7.08 per share for fiscal 2023 versus $6.75 for the comparable period in 2022.
DXR Ratings Summary
DXR Quant Ranking